Best in class? Eli Lil­ly claims a lead role awaits its CDK 4/6 drug abe­maci­clib af­ter PhI­II suc­cess

The phar­ma gi­ant says their drug abe­maci­clib gar­nered promis­ing da­ta in an in­ter­im analy­sis of MONARCH-3, a breast can­cer tri­al that matched their drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA